Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

30 ta ish

Ish: CONNECTION OF THE GENETIC POLYMORPHISM CYP3A5 AND SLCO1B1 WITH THE MUSCULAR SYMPTOMS, CAUSED BY SIMVASTATIN IN PATIENTS WITH CHD, ETHNIC UZBEKS: RESULTS OF THE CASE-CONTROL STUDY

  1. Yaşlı Kadınlarda Üreme Sağlığı

    Kokanalı, Demet, Engin Üstün, Yaprak

    Preprint192 iqtibos
    ABI

  2. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

    Colin Baigent, Anthony Keech, Patricia M. Kearney +8

    Sharh maqola20057 iqtibos
    ABI

  3. Sarlavhasiz

    Boshqa5 iqtibos
    ABI

  4. <i>SLCO1B1</i> Variants and Statin-Induced Myopathy — A Genomewide Study

    The SEARCH Collaborative Group

    Maqola20084 iqtibos
    ABI

  5. Lipid-lowering response to statins is affected by CYP3A5 polymorphism

    Kari T. Kivistö, Mikko Niemi, Elke Schaeffeler +6

    Maqola20044 iqtibos
    ABI

  6. Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects

    William E. Evans, Howard L. McLeod

    Maqola20034 iqtibos
    ABI

  7. Effect of Polymorphic <i>CYP3A5</i> Genotype on the Single‐Dose Simvastatin Pharmacokinetics in Healthy Subjects

    Kyoung‐Ah Kim, Pil‐Whan Park, Ock‐Je Lee +2

    Maqola20064 iqtibos
    ABI

  8. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000

    Earl S. Ford, Umed A. Ajani, Janet B. Croft +5

    Maqola20073 iqtibos
    ABI

  9. <i>CYP3AP1*3</i>Allele Is Associated With Lipid-Lowering Efficacy of Simvastatin and Atorvastatin in Chinese Women

    Yanpeng Li, Lirong Zhang, Min Jia +1

    Maqola20103 iqtibos
    ABI

  10. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment

    Marilu Fiegenbaum, F DASILVEIRA, C VANDERSAND +4

    Maqola20053 iqtibos
    ABI

  11. CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort

    Joseph P. Kitzmiller, Jasmine A. Luzum, Damiano Baldassarre +2

    Maqola20143 iqtibos
    ABI

  12. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity

    Fumihiro Sata

    Maqola20003 iqtibos
    ABI

  13. Needed: Pragmatic Clinical Trials for Statin-Intolerant Patients

    Patricia D. Maningat, Jan L. Breslow

    Maqola20113 iqtibos
    ABI

  14. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

    Erik S.G. Stroes, Paul D. Thompson, Alberto Corsini +37

    Sharh maqola20153 iqtibos
    ABI

  15. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

    Marja K. Pasanen, Mikko Neuvonen, Pertti J. Neuvonen +1

    Maqola20063 iqtibos
    ABI

  16. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

    Peter Kuehl, Jiong Zhang, Yvonne Lin +16

    Maqola20013 iqtibos
    ABI

  17. Sarlavhasiz

    Boshqa3 iqtibos
    ABI

  18. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  19. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  20. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  21. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  22. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  23. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  24. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  25. Sarlavhasiz

    Boshqa2 iqtibos
    ABI